Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tebanicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 3/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 3/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tebanicline SCHEMBL29711092 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL677444 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL120179 | 1.00 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL15663029 | 0.98 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL15663031 | 0.98 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Tebanicline SCHEMBL7407195 | 0.98 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL905233 | 0.89 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL8440116 | 0.89 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8437569 | 0.88 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8435785 | 0.88 | CHRNA3 (0.97) | CHRNA3CHRNB2CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| CN-119212689-A | Nicotinic acetylcholine receptor antagonists/blockers for increasing dopamine | 张燕峰 | 2024-12-27 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | claimed |
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2006092691-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| US-20050014779-A1 | Compositions and methods for treatment of neurological disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | claimed |
| EP-1434573-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | Omeros Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030139387-A1 | Compositions and methods for treatment of neurological disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-24 | — | — | US | claimed |
| WO-2003057140-A2 | COMPOSITION AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA (US) | 2003-07-17 | — | — | WO | claimed |
| US-20020028798-A1 | Irrigation solution and method for inhibition of pain and inflammation | OMEROS MEDICAL SYSTEMS | 2002-03-07 | — | — | US | claimed |
| WO-2000023062-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN AND INFLAMMATION | OMEROS MEDICAL SYSTEMS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-6054451-A | THE EFFECTIVENESS OF (R) OR (S) 5-(2-AZETIDINYLMETHOXY)-2-CHLOROPYRIDINE, IS SIGNIFICANTLY POTENTIATED BY ADMINISTERING AN ANALGESIC-POTENTIATING AMOUNT FOR SAID ANALGESIC OF AT LEAST ONE NONTOXIC NMDA RECEPTOR | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-04-25 | — | — | US | claimed |
| WO-1999053922-A1 | ANALGESIC COMPOSITIONS COMPRISING NMDA-ANTAGONISTS AND ABT-594 | ALGOS PHARMACEUTICAL CORPORATION (US) | 1999-10-28 | — | — | WO | claimed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173318-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885CHRNA3 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.